The litigation centers on a period between April 16, 2025, and May 4, 2026, during which GeneDx shares plummeted by 49.2%, resulting in a loss of $33.42 per share. This decline followed the company's disclosure of a $31.2 million impairment charge and a significant reduction in annual revenue guidance, which was slashed by approximately $65 million.

CEO Katherine Stueland and CFO Kevin Feeley are named as individual defendants. The complaint invokes Section 20(a) of the Securities Exchange Act, arguing that both executives exercised control over corporate communications and financial disclosures. Plaintiffs contend that Stueland and Feeley possessed material non-public information concerning the underperformance of the Fabric Genomics acquisition while publicly maintaining that the integration was on track. The action further highlights Sarbanes-Oxley certifications signed by the pair, alleging these filings were either knowingly or recklessly misleading regarding the company's financial health and disclosure controls.